Novo invested an additional $4.5m as Alder raised a sum well below the $115m initially targeted.

The pharmaceutical company, backed by Johnson & Johnson, has gone public, but at a price well below its range.

The company's existing shareholders, which include Baxter, Takeda, Lundbeck and Shire, provided the funding, which will be used to advance its depression treatments.

The oncology software developer has now raised $138m, following a second consecutive round led by Google Ventures, and will shortly acquire Altos Solutions.

Salesforce.com featured in a Lightspeed Partners-led round that increased Evariant's overall funding to over $26m.

The biopharmaceutical startup is developing treatments for cancer and infectious diseases.

The company, which develops treatments based on changes in the gut microbiome, has now raised $22m in total.

The Novo-backed protein testing system developer has not decided on how it will invest the proceeds from the initial public offering.

The GSK-backed fungal infection drug developer has raised the maximum again from the $55m initially targeted from an IPO in which Sanofi will become its largest shareholder.